Familial Hypercholesterolemia
Esperion Therapeutics Inc. focuses on clinical research in heterozygous familial hypercholesterolemia, with an emphasis on inherited lipid disorders that require targeted management of elevated LDL cholesterol.
- Heterozygous familial hypercholesterolemia
- Inherited dyslipidemia
- Cholesterol-lowering therapy
The sponsor’s research activity includes evaluation in pediatric patients and reflects interest in age-specific treatment considerations for children and adolescents living with this condition.
Paediatric Lipid Disorders
Clinical work supported by Esperion Therapeutics extends to children and adolescents with hypercholesterolemia, addressing therapeutic needs in younger populations affected by persistent lipid elevation.
- Paediatric patients
- Lipid metabolism
- Age-appropriate cardiovascular risk reduction
Research in this area centers on treatment use in patients aged 6 to 17 years, highlighting interest in therapeutic options suitable for early-life management of inherited cholesterol disorders.
Cardiometabolic Therapeutics
The sponsor’s trial portfolio is aligned with cardiometabolic medicine, particularly therapies designed to address abnormal cholesterol handling and the long-term risk burden associated with atherosclerotic cardiovascular disease.
- Atherosclerotic cardiovascular disease risk
- Non-statin lipid management
- Cholesterol biosynthesis and clearance
This area of interest connects lipid-focused treatment development with clinical care for patients whose genetic condition places them at increased cardiovascular risk.
Pharmacokinetic Evaluation
Esperion Therapeutics also shows interest in pharmacokinetics within its clinical studies, supporting understanding of how lipid-lowering therapy is handled in the body in younger patients with HeFH.
- Drug absorption
- Drug exposure
- Paediatric pharmacology
These research activities are relevant to the development of therapies intended for inherited cholesterol disorders across different age groups.
